Senesco Technologies, Inc. FD Jack Van Hulst Brian Ritchie President and Chief Executive Officer (brian.ritchie@fd.com) (jvanhulst@senesco.com) (212) 850-5600 (732) 296-8400 S

TECHNOLOGIES, INC. ANNOUNCES MANAGEMENT CHANGE

BRUNSWICK, N.J. - February 4, 2010 -- Senesco Technologies, Inc. ("Senesco" or

the "Company") (NYSE Amex: SNT), today announced that, on February 1, 2010,

Sascha P. Fedyszyn resigned from his position as the Company's Vice President of

Corporate Development and Secretary to pursue other interests. The

Company's current President and Chief Executive Officer, Jack Van Hulst, will

assume Mr. Fedyszyn's responsibilities and serve as the Company's

details regarding the foregoing are disclosed on the Company's Form 8-K filed

Senesco Technologies, Inc.

Technologies, Inc. is a U.S. biotechnology company, headquartered in New

Brunswick, NJ. Senesco has initiated preclinical research to trigger

or delay cell death in mammals (apoptosis) to determine if the technology is

applicable in human medicine. Accelerating apoptosis may have applications

to development of cancer treatments. Delaying apoptosis may have

applications to certain inflammatory and ischemic diseases. Senesco takes

its name from the scientific term for the aging of plant cells:

senescence. Delaying cell breakdown in plants extends freshness after

harvesting, while increasing crop yields, plant size and resistance to

environmental stress. The Company believes that its technology can be used

to develop superior strains of crops without any modification other than

delaying natural plant senescence. Senesco has partnered with leading-edge

companies engaged in agricultural biotechnology and earns research and

development fees for applying its gene-regulating platform technology to enhance

its partners' products.

statements included in this press release are forward-looking statements within

the meaning of the Private Securities Litigation Reform Act of 1995. Actual

results could differ materially from such statements expressed or implied herein

as a result of a variety of factors, including, but not limited to: the ability

to successfully transition to new management; the ability of the Company to

consummate additional financings; the development of the Company's gene

technology; the approval of the Company's patent applications; the successful

implementation of the Company's research and development programs and joint

ventures; the success of the Company's license agreements; the acceptance by the

market of the Company's products; success of the Company's preliminary studies

and preclinical research; competition and the timing of projects and trends in

future operating performance, as well as other factors expressed from time to

time in the Company's periodic filings with the Securities and Exchange

Commission (the "SEC"). As a result, this press release should be read in

conjunction with the Company's periodic filings with the SEC. The

forward-looking statements contained herein are made only as of the date of this

press release, and the Company undertakes no obligation to publicly update such

forward-looking statements to reflect subsequent events or